245 Results for "

TNBC

" in MedChemExpress (MCE) Product Catalog:
Products (245)

245 Results for "TNBC" in MCE Product Catalog:

249
249 Publications Verification
Cat. No.: HY-100381
CAS No.: 28643-80-3
Purity:  99.37%
Nigericin sodium salt is an antibiotic derived from Streptomyces hygroscopicus that act as a K +/H + ionophore, promoting K +/H + exchange across mitochondrial membranes. Nigericin sodium salt is a NLRP3 activator. Nigericin sodium salt shows promising anti-cancer activities through decreasing intracellular pH (pHi), and inactivation of Wnt/β-catenin signals. Nigericin sodium salt induces pyroptosis through caspase 1/GSDMD in TNBC .
loading...
    loading...
249
249 Publications Verification
Cat. No.: HY-127019
CAS No.: 28380-24-7
Purity:  99.43%
Nigericin is an antibiotic derived from Streptomyces hygroscopicus that act as a K +/H + ionophore, promoting K +/H + exchange across mitochondrial membranes. Nigericin is a NLRP3 activator. Nigericin shows promising anti-cancer activities through decreasing intracellular pH (pHi), and inactivation of Wnt/β-catenin signals. Nigericin induces pyroptosis through caspase 1/GSDMD in TNBC .
loading...
    loading...
110
110 Cited Publications
Cat. No.: HY-12248
CAS No.: 1439399-58-2
Purity:  99.82%
Synonyms: CB-839
Target:  

Glutaminase Autophagy

Research Areas:  

Cancer

Telaglenastat (CB-839) is a first-in-class, selective, reversible and orally active glutaminase 1 (GLS1) inhibitor. Telaglenastat selectively inhibits GLS1 splice variants KGA (kidney-type glutaminase) and GAC (glutaminase C) compared to GLS2. The IC50s are 23 nM and 28 nM for endogenous glutaminase in mouse kidney and brain, respectively. Telaglenastat inuduces autophagy and has antitumor activity .
loading...
    loading...
110
110 Cited Publications
Cat. No.: HY-12248A
CAS No.: 1874231-60-3
Synonyms: CB-839 hydrochloride
Target:  

Glutaminase Autophagy

Research Areas:  

Cancer

Telaglenastat (CB-839) hydrochloride is a first-in-class, selective, reversible and orally active glutaminase 1 (GLS1) inhibitor. Telaglenastat hydrochloride selectively inhibits GLS1 splice variants KGA (kidney-type glutaminase) and GAC (glutaminase C) compared to GLS2. The IC50s are 23 nM and 28 nM for endogenous glutaminase in mouse kidney and brain, respectively. Telaglenastat hydrochloride inudces autophagy and has antitumor activity .
loading...
    loading...
19
19 Cited Publications
Cat. No.: HY-130250
CAS No.: 2387704-62-1
Purity:  99.64%
Target:  

CDK Apoptosis

Research Areas:  

Cancer

SR-4835 is a potent, highly selective and ATP competitive dual inhibitor of CDK12/CDK13 (CDK12: IC50=99 nM, Kd=98 nM; CDK13: Kd=4.9 nM). SR-4835 acts in synergy with DNA-damaging chemotherapy and PARP inhibitors and provokes triple-negative breast cancer (TNBC) cell death .
loading...
    loading...
12
12 Cited Publications
Cat. No.: HY-15273
CAS No.: 1255580-76-7
Purity:  99.48%
UNC0638, a chemical probe, selectively inhibits G9a and GLP histone methyltransferases with IC50 of 15 nM and 19 nM, respectively. UNC0638 inhibits TNBC cell invasion and migration in vitro. UNC0638 is also an inhibitor of EHMT1/2 and induces fetal hemoglobin (HbF) expression in human erythroid progenitor cell culture. In addition, UNC0638 has anti-FMDV (foot-and-mouth disease virus) and anti-VSV (vesicular stomatitis virus) activities, with excellent potency and selectivity against multiple epigenetic and non-epigenetic targets .
loading...
    loading...
10
10 Cited Publications
Cat. No.: HY-129241
CAS No.: 330834-54-3
Purity:  99.33%
Research Areas:  

Cancer

AGX51 is the first-in-class pan-Id (inhibitors of DNA-binding/differentiation proteins) antagonist and degrader. AGX51 inhibits Id1-E47 interaction, leading to ubiquitin-mediated degradation of Ids, cell growth arrest, and viability reduction. AGX51 can inhibit TNBC and has an IC50 of about 25 nM. AGX51 can be used in cancer research.
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-101923
CAS No.: 2088939-99-3
Purity:  99.41%
Target:  

ULK Autophagy Apoptosis

Research Areas:  

Cancer

LYN-1604 is a potent UNC-51-like kinase 1 (ULK1) activator (EC50=18.94 nM) for the research of triple negative breast cancer (TNBC) .
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-101923B
CAS No.: 2310109-38-5
Purity:  99.55%
Target:  

ULK Autophagy Apoptosis

Research Areas:  

Cancer

LYN-1604 dihydrochloride is a potent UNC-51-like kinase 1 (ULK1) activator (EC50=18.94 nM) for the research of triple negative breast cancer (TNBC) .
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-128587
CAS No.: 1816989-16-8
Purity:  98.02%
Synonyms: SY-1365
Target:  

CDK

Research Areas:  

Cancer

Mevociclib (SY-1365) is a potent and first-in-class selective CDK7 inhibitor, with a Ki of 17.4 nM. Mevociclib exhibits anti-proliferative and apoptotic effects in solid tumor cell lines. Mevociclib possesses anti-tumor activity in hematological and multiple aggressive solid tumors .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-146751
CAS No.: 2757804-89-8
Purity:  99.93%
Target:  

PI3K Akt mTOR Apoptosis

Research Areas:  

Cancer

PI3K/Akt/mTOR-IN-2 is a PI3K/AKT/mTOR pathway inhibitor. PI3K/Akt/mTOR-IN-2 possess anti-cancer effects and selectivity against MDA-MB-231 cells with IC50 value of 2.29 μM. PI3K/Akt/mTOR-IN-2 can induce cancer cell cycle arrest and apoptosis .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-133129
CAS No.: 2225938-17-8
Purity:  98.92%
MS1943 is an orally active selective HyT degrader of EZH2 that effectively reduces EZH2 levels in cells. MS1943 has anticancer activity and exhibits cytotoxic effects in a variety of TNBC cells while sparing normal cells. In addition, MS1943 maintains high potency (IC50=120 nM) in inhibiting EZH2 methyltransferase activity and is highly selective for EZH2. (Structure Note: RED, EZH2 ligand (HY-148458); Blue, Hyt (HY-W001578)) .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-101567
CAS No.: 1800340-40-2
Purity:  99.75%
Research Areas:  

Cancer

BMS-986158 is a potent BET inhibitor with IC50s of 6.6 and 5 nM in NCI-H211 small cell lung cancer (SCLC) cells and MDA-MB231 triple negative breast cancer (TNBC) cells, respectively .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-19896
CAS No.: 1039455-84-9
Target:  

MDM-2/p53 Apoptosis

Research Areas:  

Cancer

COTI-2, an anti-cancer agent with low toxicity, is an orally available third generation activator of p53 mutant forms. COTI-2 acts both by reactivating mutant p53 and inhibiting the PI3K/AKT/mTOR pathway. COTI-2 induces apoptosis in multiple human tumor cell lines. COTI-2 exhibits antitumor activity in HNSCC through p53-dependent and -independent mechanisms. COTI-2 converts mutant p53 to wild-type conformation .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-120929
CAS No.: 1875036-74-0
Purity:  98.28%
Target:  

E1/E2/E3 Enzyme c-Myc

Research Areas:  

Inflammation/Immunology Cancer

BI8622 is a specific inhibitor of the ubiquitin ligase HUWE1 with an IC50 of 3.1 μM. BI8622 can decrease the protein expression levels of c-myc and glycolytic markers as well as immune modulatory markers after HUWE1 inhibition in triple-negative breast cancer (TNBC) cell lines. BI8622 significantly protects against cisplatin (HY-17394)-induced acute kidney injury (AKI). BI8622 significantly reduces the growth of multiple myeloma (MM) cell lines and induces cell cycle arrest. BI8622 can prevent HUWE1-dependent TTBK2 ubiquitination. BI8622 can be studied in research for various diseases including medulloblastoma, acute kidney injury, breast cancer and MM .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-15658
CAS No.: 1619994-68-1
Purity:  99.95%
Research Areas:  

Cancer

GSK2801, a chemical probe, is a potent, selective, orally active and cell active acetyl-lysine competitive BAZ2A and BAZ2B bromodomains inhibitor with Kd values of 136 nM and 257 nM, respectively. GSK2801 shows >50-fold selectivity for BAZ2A/B over BRD4 .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-135699
CAS No.: 1798328-24-1
Purity:  ≥95.0%
Target:  

Apoptosis Phosphatase Akt

Research Areas:  

Cancer

TD52, an Erlotinib (HY-50896) derivative, is an orally active, potent cancerous inhibitor of protein phosphatase 2A (CIP2A) inhibitor. TD52 mediates the apoptotic effect in triple-negative breast cancer (TNBC) cells via regulating the CIP2A/PP2A/p-Akt signalling pathway. TD52 indirectly reduced CIP2A by disturbing Elk1 binding to the CIP2A promoter. TD52 has less p-EGFR inhibition and has potent anti-cancer activity . TD52 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-135699A
CAS No.: 2918778-70-6
Purity:  99.90%
Target:  

Akt Phosphatase Apoptosis

Research Areas:  

Cancer

TD52 dihydrochloride, an Erlotinib (HY-50896) derivative, is an orally active, potent cancerous inhibitor of protein phosphatase 2A (CIP2A) inhibitor. TD52 dihydrochloride mediates the apoptotic effect in triple-negative breast cancer (TNBC) cells via regulating the CIP2A/PP2A/p-Akt signalling pathway. TD52 dihydrochloride indirectly reduced CIP2A by disturbing Elk1 binding to the CIP2A promoter. TD52 dihydrochloride has less p-EGFR inhibition and has potent anti-cancer activity . TD52 (dihydrochloride) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-131339
CAS No.: 2682114-54-9
Purity:  99.42%
Target:  

Aurora Kinase

Research Areas:  

Cancer

SP-96 is a highly potent, selective and non-ATP-competitive Aurora B (IC50=0.316 nM) inhibitor and shows >2000 fold selectivity against FLT3 and KIT. SP-96 shows selective growth inhibition in NCI60 screening, incluing MDA-MD-468 (GI50=107 nM). SP-96 can be used for the research of triple negative breast cancer (TNBC) .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-N0858
CAS No.: 62956-48-3
Gomisin G is a lignin from S. chinesis with anti-HIV (EC50 = 0.006 μg/mL), anti-liver cancer and anti-inflammatory activities. Gomisin G has an AKT-cyclin D1 dependent mechanism against triple-negative breast cancer (TNBC) cells through suppressing phosphorylation rather than inducing apoptosis. Gomisin G can inhibit AKT phosphorylation. Gomisin G can cause cell cycle arrest in the G1 phase. Gomisin G can be studied in research for diseases such as HIV, breast and liver cancers .
loading...
    loading...